Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza a vaccine in HIV-1-infected patients

Clinical Infectious Diseases

Volumn 52, Issue 1, 2011, Pages 122-127

  Bickel, Markus ^a   Von Hentig, Nils ^a   Wieters, Imke ^a   Khaykin, Pavel ^a   Nisius, Gabi ^a   Haberl, Annette ^a   Stephan, Christoph ^a   Herrmann, Eva ^b   Doerr, Hans W ^b   Brodt, Hans Reinhard ^a   Allwinn, Regina ^b  

^a HIVCENTER ^*  (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INFLUENZA VACCINE;

ADULT; ANTIBODY TITER; ARTHRALGIA; BLOOD SAMPLING; BODY MASS; CD4 LYMPHOCYTE COUNT; CHRONIC HEPATITIS; CLINICAL TRIAL; DIARRHEA; DISEASE DURATION; DRUG FEVER; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; HEMAGGLUTINATION INHIBITION; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; INFLUENZA A (H1N1); INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; PANDEMIC INFLUENZA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; STOMATITIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINATION; VACCINES, SUBUNIT;

EID: 79951718135     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq003     Document Type: Review

References (31)

1. Centers for Disease Control Prevention. Use of influenza A/H1N1 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 MMWR Morbid Mortal Wkly Rep 2009;58(RR-10).
2. RKI. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut, Impfung gegen die Neue Influenza (H1N1). Epid Bull 2009;50:513-524.
3. Bickel M, Wieters I, Khaykin P, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010;24(9):F31-F35.
4. Ada GL, Jones PD. The immune response to influenza infection. Curr Top Microbiol Immunol 1986;128:1-54.
5. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983;37:529-549.
6. Benne CA, Kroon FP, Harmsen M, Tavares L, Kraaijeveld CA, De Jong JC. Comparison of neutralizing haemagglutination-inhibitng antibody responses to influenza A virus vaccination of human immunodefficiency virus-infected individuals. Clin Diagn Lab Immunol 1998;5(1):114-117. (Pubitemid 28062957)
7. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182(6):1727-1737.
8. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002;20(Suppl. 5): B29-B32. (Pubitemid 35435394)
9. Iorio AM, Francisci D, Camilloni B, et al. Antibody responses HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003;21(25-26): 3629-3637. (Pubitemid 37338187)
10. Ragni MV, Ruben FL, Winkelstein A, Spero JA, Bontempo FA, Lewis JH. Antibody responses to immunization of patients with hemophilia with without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection. J Lab Clin Med 1987;109(5):545-549. (Pubitemid 17074019)
11. Nelson KE, Clements ML, Miotti P, Cohn S, Polk BF. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988;109(5):383-388.
12. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989;262:779-783. (Pubitemid 19189001)
13. Kroon FP, Rimmelzwaan GF, Roos MT, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998;12: F217-F223. (Pubitemid 28526400)
14. Brydak LB, Hryniewicz HJ, Macahala M, Horban. Humoral response to influenza vaccination in HIV-infected patients. Clin Drug Invest 1999;17:441-449. (Pubitemid 29296587)
15. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, vaccine responses. Lancet Infect Dis 2009;9(8):493-504.
16. WHO. World Health Organisation Manual on Animal Influenza Diagnosis and Surveillance 2009. http://www.who.int/vaccine-research/diseases/influenza/WHO- manual-on-animal-diagnosis-and-surveillance-2002-5.pdf. Accessed 15 March 2010.
17. Allwinn R, Geiler J, Berger A, Cinatl J, Doerr HW. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol 2010;199(2); 117-21.
18. Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines 2007. http://www.fda.gov/downloads/BiologicsBloodVaccines/Guidance- ComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf. Accessed 15 March 2010.
19. Launay O, Desaint C, Durier C, et al. Immunogenicity of one dose of Influenza A H1N1v. 2009 vaccine fromulated with and without As03A-adjuvant in HIV+ adults: preliminary report of the ANRS 151 Randomized HIVFLUVAC Trial. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections (San Francisco). 15-20 February 2010. Poster 804B.
20. Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010;24(14):2187-2192.
21. GlaxoSmithKline. GSK-clinicalstudyregister. 2010. http://www.gsk- clinicalstudyregister.com/result-comp-list.jsp?compound= H1n1+Pandemic+Influenza+Vaccine&studyType=All&phase= All&population=All&marketing=All. Accessed15 March 2010. AIDS 2010 Sep. 10; 10; 24(14) 2187-92.
22. Levine M, Beattie BL, McLean DM, Corman D. Characterization of the immune response to trivalent influenza vaccine in elderly men. J Am Geriatr Soc 1987;35:609-615. (Pubitemid 17089048)
23. Gross PA, Weksler ME, Quinnan GV Jr., Douglas RG Jr., Gaerlan PF, Denning CR. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 1987;25:1763-1765. (Pubitemid 17135189)
24. Levine M, Beattie BL, McLean DM. Comparison of one-two-dose regimens of influenza vaccine for elderly men. CMAJ 1987;137(8):722-726. (Pubitemid 17161846)
25. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009;361:2414-2423.
26. Liang XF, Wang HQ, Wang JZ, et al. Safety immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, doubleblind, randomised, placebo-controlled trial. Lancet 2009;375(9708):56-66.
27. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010;375:41-48.
28. Negredo E, Massanella M, Puig J, et al. Nadir CD4 T cell count as predictor high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis 2010;50(9):1300-1308.
29. Fowke KR, D'Amico R, Chernoff DN, et al. Immunologic virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS 1997;11(8):1013-1021. (Pubitemid 27259524)
30. Iorio AM, Alatri A, Francisci D, et al. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and-seronegative ex-intravenous drug users. Vaccine 1997;15:97-102. (Pubitemid 27060008)
31. European committee for proprietary medicinal products. Note for guidance harmonisation requirements for influenza vaccines. (CPMP/BWP/214/96). London: European Agency for the Evalation of Medicinal Products, 1990.